Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Development of a New Class of Microrna Controlled OHSV Vectors for Treatment of Glioblastoma

MAZZACURATI, LUCIA (2012) Development of a New Class of Microrna Controlled OHSV Vectors for Treatment of Glioblastoma. Doctoral Dissertation, University of Pittsburgh. (Unpublished)

This is the latest version of this item.

[img]
Preview
PDF
Primary Text

Download (2MB) | Preview

Abstract

Glioblastoma Multiforme (GBM) is a highly aggressive brain tumor for which there is no treatment. Oncolytic Viruses (OVs) are attenuated tumor-selective viruses designed to replicate in and kill tumor cells without affecting normal tissue. Herpes Simplex Virus type-1 derived oncolytic vectors (oHSV-1) are a promising and safe alternative to current GBM therapies, but the deletions that render these oHSV-1 incapable of replicating in normal tissue also compromise their lytic activity in tumor cells. Consequently, these viruses fail to effectively eradicate the tumor.
In this study, I developed a new oHSV-1, named ICP4-miR124t, whose selective replication in GBM cells does not rely on defective genes, but rather is mediated by micro (mi)RNAs differentially expressed between normal tissue and GBM. MiRNAs recognize complementary target sequences in mRNAs resulting in repression of the mRNA. MiR124 is one of the most abundant miRNAs in developing and mature neurons, but is absent in GBM since its presence is incompatible with the tumor phenotype and viability. After introducing four tandem copies of the miR124 target sequence in the 3’UTR of the HSV-1 essential ICP4 gene, I observed robust replication of the resulting ICP4-miR124t oHSV-1 in primary glioblastoma cells, while viral growth was highly impaired in the same cells upon induction of mir124. Toxicity tests involving intracranial injection of immunocompetent and immunodeficient mice showed a dramatic reduction in vector toxicity compared to unregulated control virus. Moreover, ICP4-miR124t-injected animals showed a loss of viral DNA in the brain over time, whereas an increase was observed in control virus injected animals.
In conclusion the ICP4-miR124t oHSV-1 developed in this study is promising for GBM treatment because it is capable of killing miR124-negative tumor cells as efficiently as wild-type HSV-1, while lacking toxicity for normal brain. These results are of major Public Health importance not only as a potentially more effective alternative to current inefficient GBM treatments, but also as a new paradigm to treat other kinds of tumors by taking advantage of the differential miRNA expression between tumor and normal tissue.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: University of Pittsburgh ETD
Status: Unpublished
Creators/Authors:
CreatorsEmailPitt UsernameORCID
MAZZACURATI, LUCIAl.mazzacurati@tin.it
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairFerrell, Robertrferrell@pitt.eduRFERRELL
Thesis AdvisorGrandi, Paolapag24@pitt.eduPAG24
Committee MemberBarmada, Michaelbarmada@pitt.edu BARMADA
Committee MemberNiedernhofer, Laura J niedernh@pitt.eduNIEDERNH
Committee MemberGlorioso, Joseph C , IIIglorioso@pitt.eduGLORIOSO
Date: 21 September 2012
Date Type: Completion
Defense Date: 28 June 2012
Approval Date: 21 September 2012
Submission Date: 6 June 2012
Access Restriction: No restriction; Release the ETD for access worldwide immediately.
Number of Pages: 103
Institution: University of Pittsburgh
Schools and Programs: Graduate School of Public Health > Human Genetics
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: HSV-1, Glioblastoma, MiRNA
Date Deposited: 21 Sep 2012 15:37
Last Modified: 15 Nov 2016 14:01
URI: http://d-scholarship.pitt.edu/id/eprint/13322

Available Versions of this Item

  • Development of a New Class of Microrna Controlled OHSV Vectors for Treatment of Glioblastoma. (deposited 21 Sep 2012 15:37) [Currently Displayed]

Metrics

Monthly Views for the past 3 years

Plum Analytics


Actions (login required)

View Item View Item